Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437274 | 0.87 | CNR1 (0.51) | CFDSLC22A12CNR2CNR1LMNA | |
| SCHEMBL24437144 | 0.85 | CNR1 (0.54) | SLC22A12CNR2CNR1 | |
| SCHEMBL24437315 | 0.85 | CNR1 (0.45) | CFDSLC22A12CNR2CNR1HTR3A | |
| SCHEMBL24437380 | 0.82 | SLC22A12 (0.43) | CFDSLC22A12CNR2CNR1LMNA | |
| SCHEMBL24437154 | 0.79 | DYRK1A (0.49) | CNR2CNR1LMNAHTTSMN1; SMN2 | |
| SCHEMBL24437195 | 0.79 | CNR1 (0.42) | CNR2CNR1LMNAHTTSMN1; SMN2 | |
| SCHEMBL24437163 | 0.77 | CNR1 (0.51) | SLC22A12CNR2CNR1HTTSMN1; SMN2 | |
| SCHEMBL24437134 | 0.76 | CNR1 (0.54) | CNR2CNR1 | |
| SCHEMBL19128080 | 0.75 | HDAC1 (0.49) | SLC22A12LMNAHTTSMN1; SMN2FLT1 | |
| SCHEMBL29735592 | 0.75 | HDAC1 (0.49) | SLC22A12LMNAHTTSMN1; SMN2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CFD 3394/4885SLC22A12 283/4885CNR2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.